Alpha Tau Medical (NASDAQ:DRTS) Price Target Raised to $16.00

Alpha Tau Medical (NASDAQ:DRTS) had its target price lifted by HC Wainwright from $15.00 to $16.00 in a research note published on Tuesday, MarketBeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Alpha Tau Medical’s Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($1.05) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.60) EPS.

A number of other equities research analysts also recently commented on the company. Barclays raised their target price on Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. Benchmark reaffirmed a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. Piper Sandler increased their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a report on Tuesday, May 19th. LADENBURG THALM/SH SH raised their price objective on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, Zacks Research raised shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.80.

Alpha Tau Medical Stock Performance

NASDAQ DRTS opened at $14.50 on Tuesday. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -13.94 and a beta of 1.17. The business’s 50 day moving average is $11.83 and its two-hundred day moving average is $9.33. Alpha Tau Medical has a 12-month low of $3.00 and a 12-month high of $14.75. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.09.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.36). The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.14 million. Research analysts expect that Alpha Tau Medical will post -0.92 EPS for the current year.

Insider Buying and Selling

In other Alpha Tau Medical news, CFO Raphi Levy sold 17,730 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $14.00, for a total value of $248,220.00. Following the sale, the chief financial officer owned 90,180 shares of the company’s stock, valued at approximately $1,262,520. This represents a 16.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 130,000 shares of company stock worth $1,519,143 in the last quarter. 39.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alpha Tau Medical

Several institutional investors and hedge funds have recently made changes to their positions in the business. Trifecta Capital Advisors LLC acquired a new stake in Alpha Tau Medical in the 4th quarter valued at about $48,000. Everhart Financial Group Inc. purchased a new position in Alpha Tau Medical during the 2nd quarter valued at about $126,000. Envestnet Asset Management Inc. acquired a new position in Alpha Tau Medical during the third quarter worth about $62,000. Principal Financial Group Inc. acquired a new position in Alpha Tau Medical during the first quarter worth about $132,000. Finally, Bank of America Corp DE lifted its holdings in shares of Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares in the last quarter. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

More Alpha Tau Medical News

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and raised its price target to $16 from $15, suggesting additional upside from recent trading levels. The firm’s bullish stance appears to be the main catalyst supporting DRTS. HC Wainwright forecasts strong price appreciation for Alpha Tau Medical
• Positive Sentiment: Investor enthusiasm and the higher analyst target helped Alpha Tau Medical reach a new 12-month high, reinforcing positive momentum in the stock. Alpha Tau Medical sets new 12-month high
• Neutral Sentiment: HC Wainwright’s $16 target remains above the stock’s recent price, but the firm continues to forecast ongoing losses, including estimated fiscal 2026 EPS of negative $1.05 and fiscal 2027 EPS of negative $0.60. The company is developing targeted alpha-radiation therapies for solid tumors, making clinical and commercial progress important future catalysts.
• Negative Sentiment: HC Wainwright lowered its EPS estimates for every reported period from the third quarter of 2026 through fiscal 2027. The fiscal 2026 forecast was reduced notably to a loss of $1.05 per share from $0.67, while the fiscal 2027 estimate fell to a loss of $0.60 from $0.55, signaling expectations for greater near-term cash losses.
• Negative Sentiment: CFO Raphi Levy sold 17,730 shares for approximately $248,220, reducing his direct ownership by 16.43%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which makes it a less concerning signal than discretionary selling, although it may still weigh on sentiment. Raphi Levy sells Alpha Tau Medical shares
• Negative Sentiment: Alpha Tau Medical’s latest quarterly results showed a loss of $0.50 per share, substantially worse than the expected $0.14 loss, while revenue also trailed estimates. The earnings miss adds pressure to a stock that has already advanced significantly.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.